๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
13.4K subscribers
1.33K photos
11 videos
555 files
687 links
ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู…

ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ

ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ:
ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ
ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ
ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ
ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„
ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ
ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ

ู„ู„ุชูˆุงุตู„:
Insta: hussian_8x

@AronX2bot
Download Telegram
๐Ÿ™2โค1
Breast Cancer.pdf
25.5 MB
โค5
A patient with HER2-positive MBC was initially treated with a combination of pertuzumab, trastuzumab, and a taxane.

After months, her disease progressed. Which of the following treatments is most appropriate as second-line HER2- targeted therapy?
Anonymous Quiz
65%
A) Ado-trastuzumab emtansine (TDM1)
4%
B) Imatinib
11%
C) Neratinib
9%
D) Tamoxifen
12%
E) Fulvestrant
An intramuscular agent, is approved for second line therapy of postmenopausal patients with hormone receptor-positive breast cancer either alone or in combination with targeted therapy?

A) Tamoxifen
B) Raloxifene
C) Toremifene
D) pertuzumab
E) Fulvestrant

ุจู…ุญุงุถุฑุฉ ุงู„ breast cancer ูู‚ุท ุฏูˆุงุก ูˆุงุญุฏ ู…ุฐูƒูˆุฑ ุงู†ู‡ ู†ู†ุทูŠู‡ im ูŠุนู†ูŠ ุจุฏูˆู† ู…ุง ุชูƒู…ู„ ุงู„ุณุคุงู„ ุชุฎุชุงุฑ ูˆุงู†ุช ู…ุบู…ุถ
ูˆูƒู„ุงู… ุงู„ุณุคุงู„ ู†ุตุง ู…ู† ุงู„ู…ู„ุฒู…ุฉ ู…ุงูƒูˆ ู…ุนู„ูˆู…ุฉ ู…ู…ูŠุฒุฉ ู…ุฌุฑุฏ ู…ุนู„ูˆู…ุฉ ุฏุฑุฎูŠุฉ

ูˆุฒุงุฑูŠ 25 ุฏูˆุฑ 1

#Breast_Cancer
โค5๐Ÿ’ฏ1
ู…ุฑุญุจุง ุงู†ูŠ ุทุงู„ุจุฉ ุตูŠุฏู„ุฉ ุฌุงู…ุนู‡ ุงู„ู…ุดุฑู‚
ุนู†ุฏูŠ ุจุญุซ ูŠุฎุต ุจุฎุงุฎุงุช ุงู„ุฑุจูˆ ูˆ COPD
ู…ู…ูƒู† ุชู…ู„ูˆู† ุงู„ุงุณุชุจูŠุงู† ูˆ ุงู‡ู…ุดูŠ ุฑู‚ู… collaborator code :3 ูˆ ุดูƒุฑุงู‹

https://forms.gle/hFujpBaFvBNf3kNF6
Schizophrenia.pdf
2.7 MB
โค15
Prostate Cancer.pdf
3.4 MB
โค11๐Ÿ™3
Forwarded from ARON CHAT
- ุงู„ุฑุณุงู„ู‡ ุ› ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุฏูƒุชูˆุฑ ู‡ู†ุง ุดุฑุญ ุงุฏูุงู†ุณ ู…ุฌุงู†ูŠ ุจุงู„ูƒุงู…ู„ ( ุญุงู„ูŠุง ู…ูƒู…ู„ูŠู† ุฌุงุจุชุฑูŠู† ) ู„ุงู† ุงู„ุงุบู„ุจ ูŠุฑูŠุฏ ุดุฑุญ ู„ู‡ุงูŠ ุงู„ู…ุงุฏุฉ

https://t.me/Explanation_phRam/1286
โค10
ุดุจุงุจ ุงู„ูŠูˆู… ูŠู†ุฒู„ ุงุฎุฑ ุจุงุฑุช prostate cancer

ุจุณ ุงุฑุฌุน ู„ู„ุจูŠุช ุงูƒู…ู„ู‡ ูˆุงู†ุฒู„ู‡ ุงู† ุดุงุก ุงู„ู„ู‡
โค36๐Ÿ‘2๐Ÿ™2
Prostate Cancer.pdf
17.1 MB
โค5
ุตุจุญูƒู… ุงู„ู„ู‡ ุจุงู„ุฎูŠุฑโ™ฅ๏ธ

ุดุจุงุจ ู‚ุฑุฑุช ุงู†ู‡ ุงู†ุชู‚ู„ ุจุงู„ุดุฑุญ ู„ู…ูˆุงุถูŠุน ุงู„ู†ูุณูŠุฉ

ู‚ุจู„ ู„ุง ุงูƒู…ู„ ุขุฎุฑ ู…ุญุงุถุฑุฉ ู…ู† ุงู„ูƒุงู†ุณุฑ ุงู„ูŠ ู‡ูŠ Adverse effect

ุจุญูŠุซ ุฑุญ ุชู†ุฒู„ ู…ุญุงุถุฑุงุช ุงู„ู†ูุณูŠุฉ ุทุจูŠุนูŠ
ู„ูƒู† ู…ุง ุจูŠู† ุงู„ู…ุญุงุถุฑุงุช ุฑุญ ุชู†ุฒู„ ู…ู‚ุงุทุน ู‚ุตูŠุฑุฉ ู„ู…ุญุงุถุฑุฉ ุงู„ูƒุงู†ุณุฑ ุงู„ุงุฎูŠุฑุฉ

ูŠุนู†ูŠ ู…ุญุงุถุฑุฉ ุงู„ูƒุงู†ุณุฑ ุงู„ุงุฎูŠุฑุฉ ุฑุญ ุชู†ุฒู„ ุนู„ู‰ ุงู‚ุณุงู… ู…ู…ูƒู† 5 ุงูˆ 6 ุงูˆ ุงู‚ู„
ุจุดูƒู„ ููŠุฏูŠูˆู‡ุงุช ู‚ุตูŠุฑุฉ ู…ู…ูƒู† 15 ุงูˆ 20 ุฏู‚ูŠู‚ุฉ ุญุชู‰ ู‡ู… ุงูƒู…ู„ู‡ุง ุงู„ูƒู…

ูˆุงู†ุง ุงุฏุฑูŠ ุงูƒูˆ ุจูŠูƒู… ู…ุง ูŠุฑูŠุฏ ุจุณ ูŠู‚ุฑุง ุงู„ู…ุญุงุถุฑุฉ ูˆู‡ุงูŠ ู‡ูŠ
ูˆุงู†ู…ุง ูŠุฑูŠุฏ ูŠูู‡ู…ู‡ุง ุจุงู„ุชูุตูŠู„ ุงู„ู…ู…ู„ ูƒู„ ุณุทุฑ ูˆูƒู„ ูƒู„ู…ุฉ

ู ุญุชู‰ ู…ุง ูŠุตูŠุฑ ุชุฃุฎูŠุฑ ุงูƒุซุฑ ู…ู† ุงู„ู„ุงุฒู… ูˆู„ู…ุตู„ุญุฉ ุงู„ุฌู…ูŠุน (ุฅู† ูƒุงู†ุช ุงู„ุนู„ุงุฌูŠุงุช ูˆุฒุงุฑูŠ)ุŒ ุงู† ุดุงุก ุงู„ู„ู‡ ู†ุจุฏูŠ ุจุงู„ู†ูุณูŠุฉ ู…ู† ุงู„ูŠูˆู….


ู…ูˆูู‚ูŠู† ุฌู…ูŠุนุง ๐Ÿ™

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
โค82๐Ÿ™6๐Ÿ˜4
ุทู„ุงุจ

ู‡ูˆ ุงุฐุง Hormone receptor Positive ุงูƒูŠุฏ ู†ุณุชุฎุฏู… endocrine therapy ู ุดู†ูˆ ู‡ุงู„ุชู†ุงู‚ุถ ุจู‡ุงูŠ ุงู„ุตูˆุฑุฉ

ู‡ู†ุง ุงูƒูˆ ุฎุทุฃ ุจุงู„ู…ู†ู‡ุฌ ุงู„ู…ูˆุญุฏ ูˆุฑุฌุนุช ุชุฃูƒุฏุช ู…ู† ุงู„ู…ุตุฏุฑ ูƒุงุชุจ negative ูˆู‡ุฐุง ุงู„ุตุญ

ููŠ ุญุงู„ุฉ
Hormone receptor Negative
ู‡ู†ุง ู…ุง ู†ู†ุทูŠ endocrine therapy ูˆู†ุจุฏูŠ ุจุงู„ุนู„ุงุฌ ุงู„ูƒูŠู…ูŠุงูˆูŠ


ูŠุนู†ูŠ ู…ุฎุชุตุฑ ุงู„ุนุจุงุฑุฉ ุจุดูƒู„ ูƒุงู…ู„

ููŠ ุญุงู„ุฉ Hormone receptorโ€“negative tumors (ER-/PR-)
ู‡ุฐูˆู„ ุงู„ู…ุฑุถู‰ ู…ุง ูŠุณุชููŠุฏูˆู† ู…ู† ุงู„ุนู„ุงุฌ ุงู„ู‡ุฑู…ูˆู†ูŠ ุฃุตู„ุงู‹ุŒ
ู„ุฐู„ูƒ ุงู„ุนู„ุงุฌ ุงู„ูƒูŠู…ูŠุงุฆูŠ ูŠูƒูˆู† ุฎูŠุงุฑ ุฃุณุงุณูŠ ู…ู† ุงู„ุจุฏุงูŠุฉ



ุจุญุงู„ุฉ Triple Negative Breast Cancer
ูŠุนู†ูŠ: -ER- , PR- ,HER2

ู…ุงูƒูˆ ูˆู„ุง ู‡ุฏู ู…ูˆุฌูˆุฏ ู„ุง ุฌูŠู†ูŠ ูˆู„ุง ู‡ุฑู…ูˆู†ูŠ
ุŒ ู„ุฐู„ูƒ ุงู„ุนู„ุงุฌ ุงู„ุฑุฆูŠุณูŠ ูŠูƒูˆู† ุงู„ูƒูŠู…ูŠุงูˆูŠ



ุงู…ุง ุจุงู„ุงุฎูŠุฑ ู‡ู†ุง ุฑูƒุฒูˆุง
ุงุฐุง ุงู„ุญุงู„ุฉ Hormone receptorโ€“positive tumors
ู‡ู†ุง ู†ุจุฏูŠ ุจู€ ุงู„ุนู„ุงุฌ ุงู„ู‡ุฑู…ูˆู†ูŠ ยฑ ุนู„ุงุฌ ู…ูˆุฌู‡ ุŒ ู„ูƒู†

ู†ู„ุฌุฃ ู„ู„ูƒูŠู…ูŠุงูˆูŠ ุฅุฐุง ูุดู„ ุงู„ุนู„ุงุฌ ุงู„ู‡ุฑู…ูˆู†ูŠ


ุตูุญุฉ ูกูข ุจุงู„ู…ู„ุฒู…ุฉ
ูˆุตูุญุฉ ูฆ ุจู…ู„ุฒู…ุฉ ุงู„ูˆุฒุงุฑุฉ

#Breast_Cancer

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
โค9
ุดู†ูˆ ุงู„ูุฑู‚ ุจูŠู† ู‡ุฐู‡ ุงู„ู…ุตุทู„ุญุงุช:
๐Ÿ”น Metastatic Castration Resistant Prostate Cancer
๐Ÿ”น non Metastatic Castration Resistant Prostate Cancer
๐Ÿ”น Metastatic Castration Naรฏve Prostate Cancer

๐Ÿซ† Metastatic CRPC
ุงูˆู„ ุญุงู„ุฉ ุงู„ูƒุงู†ุณุฑ ู…ู†ุชุดุฑ ูˆู…ู‚ุงูˆู… ู„ู„ู€ Castration ู…ู‚ุงูˆู… ู„ู…ุณุชูˆู‰ ุงู„ุงุฎุตุงุก (ุงู‚ู„ ู…ุณุชูˆู‰ ู…ู† Testosterone)

ูŠุนู†ูŠ ุจุงู„ุฑุบู… ู…ู† ุชู‚ู„ูŠู„ ู…ุณุชูˆู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ุงู„ุง ุงู†ู‡ ุงู„ู…ุฑุถ ุฌุงูŠ ูŠุชู‚ุฏู… ูˆู„ุง ูƒุฃู†ูˆ ู…ู‚ู„ู„ูŠู† ู…ุณุชูˆู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† (ุชุนู„ู… ุจุนูŠุด ุจุฏูˆู† ุงู„ุชุณุชูˆุณุชูŠุฑูˆู†)


๐Ÿซ† Non Metastatic CRPC
ู†ูุณ ุงู„ููƒุฑุฉ ู„ูƒู† ุงู„ูƒุงู†ุณุฑ ุจุนุฏู‡ ู…ุง ู…ู†ุชุดุฑ ุจุงู‚ูŠ ูู‚ุท ุจุงู„ุจุฑูˆุณุชุงุช, ุจุณ ู‡ู…ูŠู†ู‡ ุฌุงูŠ ูŠุชู‚ุฏู… ุฑุบู… ุชู‚ู„ูŠู„ ู…ุณุชูˆู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† (ุชุนู„ู… ูŠุนูŠุด ุจุฏูˆู† ุงู„ุชุณุชูˆุณุชูŠุฑูˆู†)

๐Ÿซ† Metastatic C Naรฏve PC
ู‡ู†ุง ุงู„ูƒุงู†ุณุฑ ู…ู†ุชุดุฑ ูˆ ุจุนุฏู†ุง ู…ุง ู…ุณูˆูŠู† Castration
ูู‡ู†ุง ุงู„ูƒุงู†ุณุฑ ุจุนุฏู‡ ูŠุนุชู…ุฏ ุนู„ู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ูˆูŠุณุญุจู‡ ูˆูŠุณุชูุงุฏ ู…ู†ู‡


ุดู†ูˆ Castration๐Ÿค”ุŸ
ุชู‚ู„ูŠู„ ู…ุณุชูˆู‰ ุงู„ุชุณุชูˆุณุชูŠุฑูˆู† ุงู„ู‰ ุงู‚ู„ ู…ุณุชูˆู‰(ู…ุณุชูˆู‰ ุงู„ุงุฎุตุงุก) ู…ู† ุฎู„ุงู„ :

Surgery (Orchiectomy)
Drugs(LHRH agonist)

Drugs summary:

๐Ÿ”ธEnzalutamideโž” non-metastatic CRPC
metastatic C naรฏve PC
metastatic CRPC

to delay the initiation of chemotherapy

๐Ÿ”ธDarolutamideโž” nonmetastatic CRPC

๐Ÿ”ธAbirateroneโž”
metastatic C naรฏve PC metastatic CRPC

๐Ÿ”ธDocetaxel, combined with prednisoneโž”
improves survival in CRPC

๐Ÿ”ธSipuleucel Tโž”
asymptomatic or minimally symptomatic metastatic CRPC

๐Ÿ”ธOlaparib and rucaparibโž”
metastatic CRPC

๐Ÿ”ธRadium223โž”
metastatic CRPC with symptomatic primary bone metastases



#Prostate_Cancer

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
โค5
A 54 years old male diagnosed with prostate cancer and was preseribed relugolix, the major advantage of GnRH antagonists over LHRH agonists is:
Anonymous Quiz
11%
A) It is administered as a subcutaneous injection
5%
B) It has no effect on QTC interval
4%
C) No hyperglycemia risk
74%
D) It lacks tumor flare
5%
E) No hypertriglyceridemia risk
โค2